Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 21, 2014; 20(35): 12574-12580
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12574
Table 1 Patient characteristics
Patient characteristicsn (%)
Age at diagnosis (yr)262 (34)
Gender
Male127 (48.5)
Female135 (51.5)
Extent of the disease
Proctitis43 (16.4)
Proctosigmoiditis47 (17.9)
Left-sided colitis50 (19.1)
Pancolitis114 (43.5)
Unknown8 (3.0)
Extraintestinal manifestations
Eyes2 (0.8)
Skin6 (2.3)
Joints50 (19.1)
Immunosuppressive therapy
Azathioprine98 (94.2)
6-Mercaptopurine23 (22.1)
Infliximab36 (34.6)
Adalimumab3 (2.9)
Golimumab1 (1.0)
Methotrexate3 (2.9)
Miscellaneous12 (11.5)
Reason for IT
Steroid-refractory disease course40 (38.4)
Chronic-active disease course31 (29.8)
Steroid-dependent disease course27 (26.0)
Miscellaneous6 (5.8)
Table 2 Independent parameters associated with a severe course of ulcerative colitis, predicting the risk for subsequent necessity of immunosuppressive therapy (multivariate analysis)
ParameterOR95%CIP value
Age at diagnosis0.981 (per year)0.967-0.9950.009
Gender (female)1.30.9-2.00.156
Steroid therapy at diagnosis2.41.6-3.7< 0.001
Hospitalisation at diagnosis2.51.5-4< 0.001
Extent of the disease< 0.001
Proctitis1
Procto-sigmoiditis3.51.4-8.60.007
Left-sided colitis5.31.6-15.30.002
Pancolitis6.12.1-17.50.001
Result of steroid therapy< 0.001
No steroids1
Remission5.21.4-20.30.016
Response15.34.7-50< 0.001
Steroid-dependent50.815.2-170< 0.001
Steroid-refractory34.810.5-114.8< 0.001